Evaluation of the activities of rifabutin combined with atovaquone or low-dose of cotrimoxazole for prevention of pneumocystosis and toxoplasmosis in a dual infection rat model.
Brun-Pascaud
M
M
INSERM U 13. Hôpital Bichat-Clande Bernard, Paris, France.
Chau
F
F
Rajagopalan-Levasseur
P
P
Derouin
F
F
Girard
P M
PM
D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D053626:Atovaquone; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D009285:Naphthoquinones / Q000627:therapeutic use*; D011010:Pneumocystis / Q000187:drug effects; D011020:Pneumonia, Pneumocystis / Q000150:complications / Q000517:prevention & control*; D051381:Rats; D017208:Rats, Wistar; D017828:Rifabutin / Q000627:therapeutic use*; D014122:Toxoplasma / Q000187:drug effects; D014124:Toxoplasmosis, Animal / Q000150:complications / Q000517:prevention & control*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use*
D000935:Antifungal Agents; D000981:Antiprotozoal Agents; D009285:Naphthoquinones; D017828:Rifabutin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D053626:Atovaquone